The twenty-first century is beginning with a sharp turn in the field of cancer therapy.
Molecular targeted therapies against specific oncogenic events are now possible. The BCR …

Imatinib as a paradigm of targeted therapies Page 10 Imatinib as a Paradigm of Targeted
Therapies Brian J. Druker Howard Hughes Medical Institute, Cancer Institute, Oregon Health …

Purpose To evaluate the basic pharmacokinetic (PK) characteristics of imatinib mesylate
and assess the relationship between the PK and pharmacodynamic (PD) properties of the …

The protein kinase Akt is activated in a wide variety of cancers, and this activation results in
enhanced resistance to apoptosis through multiple mechanisms. This article reviews the …

Imatinib mesylate (STI571) is a competitive Bcr-Abl tyrosine kinase inhibitor and has yielded
encouraging results in treatment of chronic myelogenous leukemia (CML) and …

Cell cycle arrest by FoxO transcription factors involves transcriptional repression of cyclin D,
although the exact mechanism remains unclear. In this study, we used the BCR-ABL …

Despite the remarkable clinical response rates to imatinib in the treatment of bcr-abl
leukemic patients, pharmacokinetic data on this relatively novel substance are needed to …

The ABL tyrosine kinase inhibitor imatinib mesylate is highly effective in the treatment of
CML and is increasingly used in the stem cell transplantation (SCT) setting. Since ABL …

Caspase-independent programmed cell death can exhibit either an apoptosis-like or a
necrosis-like morphology. The ABL kinase inhibitor, imatinib mesylate, has been reported to …

Since interferon-α and imatinib (IM; STI571, Glivec, Gleevec) are effective for the treatment of
chronic myeloid leukemia (CML), and their mechanisms of action are different, we designed …